title: Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study.
abstract: There is consensus that young patients with mantle cell lymphoma (MCL) should receive intensive immunochemotherapy regimens, but optimal treatment of elderly patients as well for as patients with limited or indolent disease is not defined. Our aim was to evaluate and compare outcome in relation to prognostic factors and first-line treatment in patients with MCL in a population-based data set. Data were collected from the Swedish and Danish Lymphoma Registries from the period of 2000 to 2011. A total of 1389 patients were diagnosed with MCL. During this period, age-standardized incidence MCL increased, most prominently among males. Furthermore, male gender was associated with inferior overall survival (OS) in multivariate analysis (hazard ratio [HR] = 1.36; P = .002). Forty-three (3.6%) patients with stage I-II disease received radiotherapy with curative intent, showing a 3-year OS of 93%. Twenty-nine (2.4%) patients followed a watch-and-wait approach and showed a 3-year OS of 79.8%. Among patients receiving systemic treatment, rituximab (n = 766; HR = 0.66; P = .001) and autologous stem cell transplant (n = 273; HR = 0.55; P = .004) were independently associated with improved OS in multivariate analysis. Hence, by a population-based approach, we were able to provide novel data on prognostic factors and primary treatment of MCL, applicable to routine clinical practice.
authors.affiliation: Department of Oncology, Skåne University Hospital, Lund, Sweden;
authors.forename: Anna
authors.initials: A
authors.lastname: Abrahamsson
authors.affiliation: Department of Oncology, Skåne University Hospital, Lund, Sweden;
authors.forename: Alexandra
authors.initials: A
authors.lastname: Albertsson-Lindblad
authors.affiliation: Department of Hematology, Rigshospitalet, Copenhagen, Denmark;
authors.forename: Peter N
authors.initials: PN
authors.lastname: Brown
authors.affiliation: Department of Hematology, Karolinska University Hospital, Stockholm, Sweden;
authors.forename: Stefanie
authors.initials: S
authors.lastname: Baumgartner-Wennerholm
authors.affiliation: Department of Hematology, Roskilde Hospital, Roskilde, Denmark;
authors.forename: Lars M
authors.initials: LM
authors.lastname: Pedersen
authors.affiliation: Department of Hematology, Aarhus University Hospital, Aarhus, Denmark;
authors.forename: Francesco
authors.initials: F
authors.lastname: D'Amore
authors.affiliation: Department of Hematology, Sahlgrenska University Hospital, Gothenburg, Sweden;
authors.forename: Herman
authors.initials: H
authors.lastname: Nilsson-Ehle
authors.affiliation: Department of Hematology, Aalborg University Hospital, Aalborg, Denmark; and.
authors.forename: Paw
authors.initials: P
authors.lastname: Jensen
authors.affiliation: Department of Hematology, Herlev University Hospital, Copenhagen, Denmark.
authors.forename: Michael
authors.initials: M
authors.lastname: Pedersen
authors.affiliation: Department of Hematology, Rigshospitalet, Copenhagen, Denmark;
authors.forename: Christian H
authors.initials: CH
authors.lastname: Geisler
authors.affiliation: Department of Oncology, Skåne University Hospital, Lund, Sweden;
authors.forename: Mats
authors.initials: M
authors.lastname: Jerkeman
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D064592:Autografts; D018572:Disease-Free Survival; D015994:Incidence; D020522:Lymphoma, Mantle-Cell / Q000401:mortality / Q000628:therapy; D009367:Neoplasm Staging; D011878:Radiotherapy; D012042:Registries; D012189:Retrospective Studies; D000069283:Rituximab; D012737:Sex Factors; D033581:Stem Cell Transplantation; D015996:Survival Rate
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab